MD MEDICAL GROUP OPENS NEW SURGERY CENTRE «LAPINO-2»
|Download file (235 K)|
17 September, Moscow – MD Medical Group Investments Plc («MD Medical Group», «MDMG» or the «Company» – LSE: MDMG), a leading Russian private healthcare provider, announces that it has inaugurated the new surgery centre «Lapino-2» – the second stage of the multi-disciplinary hospital Lapino.
The hospital’s construction began on 30 May 2018. The Group’s total investment in the project amounted to 3.9 billion roubles. The “Lapino-2” hospital is one of the largest projects in the healthcare sector conmmisioned in the recent period in Russia.
The new 6-storey surgery building with an area of 18,500 sq m will provide medical services for all family members, including those under the MHI program. “Lapino-2” is to carry out 12,000 operations, about 40,000 in-patient days and more than 180,000 out-patient treatments per year. A multi-level parking facility in a separate building for 277 cars was built near the hospital for the convenience of patients (CAPEX 300 million rubles).
“Lapino-2” includes departments for cardiovascular surgery, stomatology, including oral and maxillofacial surgery, a diagnostical department, a hemodialysis department, an intensive care unit with 13 beds, 6 operating theatres for planned surgeries and 2 for emergency surgeries.
“Lapino-2” houses a state-of-the-art oncology centre that offers a full cycle medical service on a high level with adherence to modern world protocoles – from screening and diagnosis verification to high-tech oncosurgical care, chemoradiotherapy and oncological rehabilitation.
The new oncocentre includes departments with the following specialization: oncohematology, chemotherapy, general oncology, thoracoabdominal oncology, coloproctology, oncogynaecology, oncourology, head and neck tumors. The chemotherapy department that opened at the Lapino hospital in the beginning of 2020 will be significantly expanded. The oncology centre will provide 18,000 cycles of chemotherapy, including immunotherapy and targeted therapy, as well as neoadjuvant therapy year-on-year. Medical service will be provided on a commercial basis and under the VHI and MHI programs. For this purpose a team of leading Russian oncologists has joined the Company.
The hospital will also operate a state-of-the-art microbiological laboratory offering a full range of diagnostic testing, in particular with time-of-flight mass metering, flow cytometry for examining the patient's immune status, as well as an infectious serology unit. The PCR laboratory will conduct studies to analyze the impact of various pathogens of viruses (including COVID-19), which will help to test various vaccines.
“Lapino-2” will operate in accordance with the Company’s customary high standard of medical care. The surgery building has world-class equipment produced by GE Healthcare, Philips, Siemens, Olympus, Origio, Draeger, Lumenis, Getinge, Maquet. The dental department is equipped by KAVO, Sirona, Renfer, Wasserman, SAM, EMS, as well as Matrix Parker Hannifin Corporation. PCR equipment produced by Bio-Rad, Elmi, Eppendorf was installed in the new laboratory.
Mark Kurtser, CEO of MD Medical Group, said:
“The launch of the “Lapino-2” surgery centre constitutes an important step in the development of the Company. The Lapino hospital has been operating successfully for many years and acquired in the course of time the confidence and gratitude of thousands of patients. Today it rises to a new level in providing planned and emergency medical help. Launching this large scale centre and new departments, Lapino is becoming a major multifunctional medical centre which provides 24/7 medical help to patients with various problems”.
This announcement contains inside information.
For further information please contact:
MD Medical Group Investments Plc
Tel: +7 (495) 139-87-40, ext. 16329
Sergii Pershyn: +1 929 855 8188
About MD Medical Group
MD Medical Group is a leading provider in the highly attractive Russian private healthcare service market. The company manages 42 modern healthcare facilities, including 6 hospitals and 36 out-patient clinics in Moscow and the Moscow Region, St. Petersburg, Ufa, Perm, Samara and the Samara Region, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, Barnaul, Vladimir, Tyumen, Voronezh, Nizhny Novgorod, Volgograd, Tula, Kazan, Vladivostok, Krasnodar and Rostov-on-Don.
The Company’s shares have been listed on the London Stock Exchange (LSE ticker “MDMG”) in the form of Global Depositary Receipts (GDRs) since 12 October 2012.
This press release contains forward looking statements, which are based on the Company’s current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company’s ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements. No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.
2020 2019 2018 2017 2016 2015 2014 2013 2012